Abstract
This viral disease may appear as an extensive and severe true primary infection, as a more localized first-episode genital infection, or as a focal recurrent infection. Biologic differences between type 1 and type 2 virus are major factors in determining the natural history of recurrent disease. Although the most promising new drug currently under study for use against herpes simplex virus is a nucleoside analogue called acycloguanosine (acyclovir), an ill omen on the horizon of long-term prophylaxis against recurrent disease is the emergence of acyclovir-resistant mutants that already have been isolated and characterized.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
